• Jessico^® Fusion contains a mix of Iblon (isoflucypram) and Inatreq™ active (fenpicoxamid)
• Jessico^® Fusion demonstrates Bayer’s commitment to research and development

Bayer has received regulatory authorisation for Jessico^® Fusion, the first co-formulation of Iblon^® (isoflucypram) and Inatreq^™ active (fenpicoxamid). The news means Jessico^® Fusion will be available to growers for use across a range of winter and spring sown cereals in spring 2026.

“Jessico^® Fusion is the latest product to form part of the Iblon^® family of fungicides all of which have demonstrated excellent efficacy against the principal foliar threats, such as Septoria leaf blotch, yellow rust and brown rust,” Greg Hanna, Fungicide Market Development for Bayer, says.

“Jessico^® Fusion maintains this performance, especially at the T2 timing, which is where we see it delivering the greatest value to growers,” he adds.

Bayer assessed Jessico^® Fusion’s activity across many seasons, including 2024 and 2025 which offered the opportunity to assess its performance under uniquely challenging conditions.

“In both the 2024 and 2025 seasons when conditions were either extremely wet or exceptionally dry, Jessico^® Fusion performed impressively, frequently delivering the greatest yield uplift of any product in trial. This suggests the active substances in Jessico^® Fusion combine to deliver an excellent broad spectrum disease control solution well-suited to T2 but with the flexibility to be used at T1 in higher Septoria pressure conditions.”

The prolonged dry weather of 2025 made assessing the disease control performance of all fungicides a challenge. These conditions, however, were ideal for assessing any crop greening benefits fungicides deliver over and above what might otherwise be expected. In this situation, the Iblon component of Jessico^® Fusion delivered impressively sustaining green leaf area beyond that typically seen with Ascra^® Xpro^® (bixafen + fluopyram + prothioconazole).

“The 2025 season proved to be an extreme challenge but one that provided an opportunity to assess the physiological benefits of a fungicide. The extended chlorophyll activity seen with Iblon in earlier trials was repeated with Jessico^® Fusion with treated crops delivering a positive yield return in the absence of disease but under intense drought stress,” Mr Hanna says.

The performance of Jessico^® Fusion at either the T1 or T2 timing and as part of a balanced programme was also investigated as part of Bayer’s market development trials.

“The inclusion of Inatreq^® in Jessico^® Fusion makes T2 the obvious timing and this is supported by the trials data. In contrast, the inclusion of fluopyram and prothioconazole with Iblon^® in Plaxium^® give it the edge at T1. The two products deliver excellent control of the main disease threats at each timing giving growers and their agronomists the protection needed and the flexibility to apportion spend within the programme depending on priorities,” he adds.